CD30: seeing is not always believing
- PMID: 25721040
- DOI: 10.1182/blood-2015-01-622480
CD30: seeing is not always believing
Abstract
Although most investigators are well aware of the incredible success of brentuximab vedotin in the treatment of patients with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), the study by Jacobsen and colleagues in this issue of Blood demonstrates surprising activity of this agent in patients with B-cell non-Hodgkin lymphoma (NHL).
Comment on
-
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8. Blood. 2015. PMID: 25573987 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

